Cargando…

Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice

A recent type 1 diabetes (T1D) clinical trial of rituximab (a B cell-depleting anti-CD20 antibody) achieved some therapeutic benefit in preserving C-peptide for a period of approximately nine months in patients with recently diagnosed diabetes. Our previous data in the NOD mouse demonstrated that co...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarikonda, Ghanashyam, Sachithanantham, Sowbarnika, Manenkova, Yulia, Kupfer, Tinalyn, Posgai, Amanda, Wasserfall, Clive, Bernstein, Philip, Straub, Laura, Pagni, Philippe P., Schneider, Darius, Calvo, Teresa Rodriguez, Coulombe, Marilyne, Herold, Kevan, Gill, Ronald G., Atkinson, Mark, Nepom, Gerald, Ehlers, Mario, Staeva, Teodora, Garren, Hideki, Steinman, Lawrence, Chan, Andrew C., von Herrath, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566105/
https://www.ncbi.nlm.nih.gov/pubmed/23405091
http://dx.doi.org/10.1371/journal.pone.0054712
_version_ 1782258530648064000
author Sarikonda, Ghanashyam
Sachithanantham, Sowbarnika
Manenkova, Yulia
Kupfer, Tinalyn
Posgai, Amanda
Wasserfall, Clive
Bernstein, Philip
Straub, Laura
Pagni, Philippe P.
Schneider, Darius
Calvo, Teresa Rodriguez
Coulombe, Marilyne
Herold, Kevan
Gill, Ronald G.
Atkinson, Mark
Nepom, Gerald
Ehlers, Mario
Staeva, Teodora
Garren, Hideki
Steinman, Lawrence
Chan, Andrew C.
von Herrath, Matthias
author_facet Sarikonda, Ghanashyam
Sachithanantham, Sowbarnika
Manenkova, Yulia
Kupfer, Tinalyn
Posgai, Amanda
Wasserfall, Clive
Bernstein, Philip
Straub, Laura
Pagni, Philippe P.
Schneider, Darius
Calvo, Teresa Rodriguez
Coulombe, Marilyne
Herold, Kevan
Gill, Ronald G.
Atkinson, Mark
Nepom, Gerald
Ehlers, Mario
Staeva, Teodora
Garren, Hideki
Steinman, Lawrence
Chan, Andrew C.
von Herrath, Matthias
author_sort Sarikonda, Ghanashyam
collection PubMed
description A recent type 1 diabetes (T1D) clinical trial of rituximab (a B cell-depleting anti-CD20 antibody) achieved some therapeutic benefit in preserving C-peptide for a period of approximately nine months in patients with recently diagnosed diabetes. Our previous data in the NOD mouse demonstrated that co-administration of antigen (insulin) with anti-CD3 antibody (a T cell-directed immunomodulator) offers better protection than either entity alone, indicating that novel combination therapies that include a T1D-related autoantigen are possible. To accelerate the identification and development of novel combination therapies that can be advanced into the clinic, we have evaluated the combination of a mouse anti-CD20 antibody with either oral insulin or a proinsulin-expressing DNA vaccine. Anti-CD20 alone, given once or on 4 consecutive days, produced transient B cell depletion but did not prevent or reverse T1D in the NOD mouse. Oral insulin alone (twice weekly for 6 weeks) was also ineffective, while proinsulin DNA (weekly for up to 12 weeks) showed a trend toward modest efficacy. Combination of anti-CD20 with oral insulin was ineffective in reversing diabetes in NOD mice whose glycemia was controlled with SC insulin pellets; these experiments were performed in three independent labs. Combination of anti-CD20 with proinsulin DNA was also ineffective in diabetes reversal, but did show modest efficacy in diabetes prevention (p = 0.04). In the prevention studies, anti-CD20 plus proinsulin resulted in modest increases in Tregs in pancreatic lymph nodes and elevated levels of proinsulin-specific CD4+ T-cells that produced IL-4. Thus, combination therapy with anti-CD20 and either oral insulin or proinsulin does not protect hyperglycemic NOD mice, but the combination with proinsulin offers limited efficacy in T1D prevention, potentially by augmentation of proinsulin-specific IL-4 production.
format Online
Article
Text
id pubmed-3566105
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35661052013-02-12 Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice Sarikonda, Ghanashyam Sachithanantham, Sowbarnika Manenkova, Yulia Kupfer, Tinalyn Posgai, Amanda Wasserfall, Clive Bernstein, Philip Straub, Laura Pagni, Philippe P. Schneider, Darius Calvo, Teresa Rodriguez Coulombe, Marilyne Herold, Kevan Gill, Ronald G. Atkinson, Mark Nepom, Gerald Ehlers, Mario Staeva, Teodora Garren, Hideki Steinman, Lawrence Chan, Andrew C. von Herrath, Matthias PLoS One Research Article A recent type 1 diabetes (T1D) clinical trial of rituximab (a B cell-depleting anti-CD20 antibody) achieved some therapeutic benefit in preserving C-peptide for a period of approximately nine months in patients with recently diagnosed diabetes. Our previous data in the NOD mouse demonstrated that co-administration of antigen (insulin) with anti-CD3 antibody (a T cell-directed immunomodulator) offers better protection than either entity alone, indicating that novel combination therapies that include a T1D-related autoantigen are possible. To accelerate the identification and development of novel combination therapies that can be advanced into the clinic, we have evaluated the combination of a mouse anti-CD20 antibody with either oral insulin or a proinsulin-expressing DNA vaccine. Anti-CD20 alone, given once or on 4 consecutive days, produced transient B cell depletion but did not prevent or reverse T1D in the NOD mouse. Oral insulin alone (twice weekly for 6 weeks) was also ineffective, while proinsulin DNA (weekly for up to 12 weeks) showed a trend toward modest efficacy. Combination of anti-CD20 with oral insulin was ineffective in reversing diabetes in NOD mice whose glycemia was controlled with SC insulin pellets; these experiments were performed in three independent labs. Combination of anti-CD20 with proinsulin DNA was also ineffective in diabetes reversal, but did show modest efficacy in diabetes prevention (p = 0.04). In the prevention studies, anti-CD20 plus proinsulin resulted in modest increases in Tregs in pancreatic lymph nodes and elevated levels of proinsulin-specific CD4+ T-cells that produced IL-4. Thus, combination therapy with anti-CD20 and either oral insulin or proinsulin does not protect hyperglycemic NOD mice, but the combination with proinsulin offers limited efficacy in T1D prevention, potentially by augmentation of proinsulin-specific IL-4 production. Public Library of Science 2013-02-06 /pmc/articles/PMC3566105/ /pubmed/23405091 http://dx.doi.org/10.1371/journal.pone.0054712 Text en © 2013 Sarikonda et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sarikonda, Ghanashyam
Sachithanantham, Sowbarnika
Manenkova, Yulia
Kupfer, Tinalyn
Posgai, Amanda
Wasserfall, Clive
Bernstein, Philip
Straub, Laura
Pagni, Philippe P.
Schneider, Darius
Calvo, Teresa Rodriguez
Coulombe, Marilyne
Herold, Kevan
Gill, Ronald G.
Atkinson, Mark
Nepom, Gerald
Ehlers, Mario
Staeva, Teodora
Garren, Hideki
Steinman, Lawrence
Chan, Andrew C.
von Herrath, Matthias
Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
title Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
title_full Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
title_fullStr Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
title_full_unstemmed Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
title_short Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
title_sort transient b-cell depletion with anti-cd20 in combination with proinsulin dna vaccine or oral insulin: immunologic effects and efficacy in nod mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566105/
https://www.ncbi.nlm.nih.gov/pubmed/23405091
http://dx.doi.org/10.1371/journal.pone.0054712
work_keys_str_mv AT sarikondaghanashyam transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT sachithananthamsowbarnika transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT manenkovayulia transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT kupfertinalyn transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT posgaiamanda transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT wasserfallclive transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT bernsteinphilip transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT straublaura transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT pagniphilippep transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT schneiderdarius transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT calvoteresarodriguez transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT coulombemarilyne transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT heroldkevan transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT gillronaldg transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT atkinsonmark transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT nepomgerald transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT ehlersmario transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT staevateodora transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT garrenhideki transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT steinmanlawrence transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT chanandrewc transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice
AT vonherrathmatthias transientbcelldepletionwithanticd20incombinationwithproinsulindnavaccineororalinsulinimmunologiceffectsandefficacyinnodmice